charles ferté
charles ferté
Medimmune - ex: Institut Gustave Roussy
Adresse e-mail validée de medimmune.com
TitreCitée parAnnée
Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1
S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ...
Clinical Cancer Research 23 (8), 1920-1928, 2017
3842017
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial
C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ...
Cancer discovery 7 (6), 586-595, 2017
2012017
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
S Champiat, C Ferté, S Lebel-Binay, A Eggermont, JC Soria
Oncoimmunology 3 (1), e27817, 2014
1612014
Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy
R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ...
JAMA oncology 4 (11), 1543-1552, 2018
1102018
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
EJ Limkin, R Sun, L Dercle, EI Zacharaki, C Robert, S Reuzé, ...
Annals of Oncology 28 (6), 1191-1206, 2017
1092017
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
C Ferté, F André, JC Soria
Nature reviews clinical oncology 7 (7), 367, 2010
1072010
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ...
The Lancet Oncology 19 (9), 1180-1191, 2018
942018
Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial
C Jovelet, E Ileana, MC Le Deley, N Motté, S Rosellini, A Romero, ...
Clinical Cancer Research 22 (12), 2960-2968, 2016
702016
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials
C Ferté, M Fernandez, A Hollebecque, S Koscielny, A Levy, C Massard, ...
Clinical Cancer Research 20 (1), 246-252, 2014
612014
Hyperprogressive disease: recognizing a novel pattern to improve patient management
S Champiat, R Ferrara, C Massard, B Besse, A Marabelle, JC Soria, ...
Nature reviews Clinical oncology 15 (12), 748-762, 2018
592018
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues
C Ferté, A Paci, M Zizi, DB Gonzales, A Goubar, C Gomez-Roca, ...
European Journal of Cancer 47 (15), 2249-2255, 2011
512011
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET …
C Ferte, S Koscielny, L Albiges, L Rocher, JC Soria, R Iacovelli, Y Loriot, ...
European urology 65 (4), 713-720, 2014
482014
Tumour growth rates and RECIST criteria in early drug development
C Gomez-Roca, S Koscielny, V Ribrag, C Dromain, I Marzouk, F Bidault, ...
European journal of cancer 47 (17), 2512-2516, 2011
472011
Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review
JE Bibault, I Fumagalli, C Ferté, C Chargari, JC Soria, E Deutsch
Cancer and Metastasis Reviews 32 (3-4), 479-492, 2013
392013
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons
A Hollebecque, D Malka, C Ferté, M Ducreux, V Boige
European Journal of Cancer 51 (3), 327-339, 2015
342015
IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy
C Ferté, Y Loriot, C Clémenson, F Commo, A Gombos, JE Bibault, ...
Molecular cancer therapeutics 12 (7), 1213-1222, 2013
332013
Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology
C Ferté, AD Trister, E Huang, BM Bot, J Guinney, F Commo, S Sieberts, ...
Clinical Cancer Research 19 (16), 4315-4325, 2013
302013
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
L Verlingue, D Malka, A Allorant, C Massard, C Ferté, L Lacroix, ...
European Journal of Cancer 87, 122-130, 2017
292017
“Classical 3+ 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents
N Penel, N Isambert, P Leblond, C Ferte, A Duhamel, J Bonneterre
Investigational new drugs 27 (6), 552, 2009
292009
Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy …
D Ou, P Blanchard, S Rosellini, A Levy, F Nguyen, RTH Leijenaar, ...
Oral oncology 71, 150-155, 2017
272017
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20